Mostrando 6 resultados de: 6
Filtros aplicados
Publisher
Circular Farmaceutica(1)
European Journal of Pharmaceutical Sciences(1)
Frontiers in Aging Neuroscience(1)
Journal of Controlled Release(1)
Nanomaterials(1)
Área temáticas
Enfermedades(5)
Farmacología y terapéutica(4)
Fisiología humana(3)
Medicina y salud(2)
Ginecología, obstetricia, pediatría, geriatría(1)
Área de conocimiento
Nanopartícula(2)
Biotecnología(1)
Ciencia de materiales(1)
Cáncer(1)
Farmacología(1)
Origen
scopus(6)
A metabolic perspective of late onset Alzheimer's disease
ReviewAbstract: After decades of research, the molecular neuropathology of Alzheimer's disease (AD)is still one of tPalabras claves:Alzheimer's disease, c-Jun N-terminal kinase inhibitors, Insulin, Licochalcone A, neuroinflammation, Reticulum stress, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E., Zárate C.B.Fuentes:scopusCurrent applications of nanoemulsions in cancer therapeutics
ReviewAbstract: Nanoemulsions are pharmaceutical formulations composed of particles within a nanometer range. They pPalabras claves:Cáncer, Multifunctional nanoemulsions, Targeted deliveryAutores:Antoni Camins, Cano A., Dias-Ferreira J., Espina M., Ettcheto M., García M.L., Guerra M., Lopez-Machado A.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusNanopartícules polimèriques d'epigalocatequina-3-galat, un enfocament nanotecnològic per tractar la malaltia d'Alzheimer
ArticleAbstract:Palabras claves:Autores:Antoni Camins, Cano A., Espina M., Ettcheto M., García M.L., López A.L., Sanchez-Lopez E.Fuentes:scopusThe Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer’s Dementia
ReviewAbstract: Nowadays, Alzheimer’s disease (AD) is a severe sociological and clinical problem. Since it was firstPalabras claves:Alzheimer’s disease, Insulin Resistance, Mediterranean diet, neuroinflammation and neurodegeneration, obesity, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Casadesús G., Espinosa-Jimenez T., Ettcheto M., Folch J., García M.L., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusThiazolidinedione as an alternative to facilitate oral administration in geriatric patients with Alzheimer's disease
ArticleAbstract: Pioglitazone (PGZ) is a member of the thiazolidinedione (TZDs) family of drugs and it is primarily uPalabras claves:Alzheimer's disease, Geriatric patients, Mucosal permeation, Oral administration, Pioglitazone, ThiazolidinedionesAutores:Calpena A.C., Espina M., García M.L., Gonzalez-Pizarro R., Lupe Carolina Espinoza, Rodríguez-Lagunas M.J., Silva-Abreu M.Fuentes:scopus